title: Management of endometrial cancer in Asia: consensus statement from the Asian Oncology Summit 2009.
abstract: Endometrial cancer is one of the gynaecological cancers that carries good overall prognosis because it is often detected at early stages of disease. The International Federation of Gynecology and Obstetrics replaced clinical staging with surgical staging in 1988 and updated the system in 2009. Controversies remain regarding the recommended screening protocol for women with a high risk of endometrial cancer, the role and benefit of retroperitoneal lymph-node dissection, the necessity of ovarian resection, the benefit and type of adjuvant radiation therapy, and the safety of hormone-replacement therapy after treatment. This article reviews the available evidence for optimum management of endometrial cancer and how management strategies can be applied in Asian countries with different levels of health-care resource availability and economic development. An overview of the literature for endometrial-cancer screening, diagnosis, and management is discussed. Consensus statements are formulated on the basis of basic, limited, enhanced, and maximum health-care resource availability, using the framework provided by the Breast Health Global Initiative.
authors.affiliation: Department of Obstetrics and Gynecology, Bangkok Metropolitan Administration Medical College and Vajira Hospital, Bangkok, Thailand.
authors.forename: Siriwan
authors.initials: S
authors.lastname: Tangjitgamol
authors.forename: Benjamin O
authors.initials: BO
authors.lastname: Anderson
authors.forename: Hui Ti
authors.initials: HT
authors.lastname: See
authors.forename: Chawalit
authors.initials: C
authors.lastname: Lertbutsayanukul
authors.forename: Nakarin
authors.initials: N
authors.lastname: Sirisabya
authors.forename: Tarinee
authors.initials: T
authors.lastname: Manchana
authors.forename: Arunachalam
authors.initials: A
authors.lastname: Ilancheran
authors.forename: Khai Mun
authors.initials: KM
authors.lastname: Lee
authors.forename: Siew Eng
authors.initials: SE
authors.lastname: Lim
authors.forename: Yin-Nin
authors.initials: YN
authors.lastname: Chia
authors.forename: Efren
authors.initials: E
authors.lastname: Domingo
authors.forename: Young-Tak
authors.initials: YT
authors.lastname: Kim
authors.forename: Chyong-Huey
authors.initials: CH
authors.lastname: Lai
authors.forename: Ahmad Zailani Hatta Mohd
authors.initials: AZ
authors.lastname: Dali
authors.forename: Wisit
authors.initials: W
authors.lastname: Supakapongkul
authors.forename: Sarikapan
authors.initials: S
authors.lastname: Wilailak
authors.forename: Eng-Hseon
authors.initials: EH
authors.lastname: Tay
authors.forename: John
authors.initials: J
authors.lastname: Kavanagh
mesh_terms: D001208:Asia / Q000453:epidemiology; D017024:Chemotherapy, Adjuvant; D003226:Congresses as Topic; D003362:Cost-Benefit Analysis; D003906:Developing Countries / Q000191:economics; D016527:Drug Costs; D042241:Early Diagnosis; D016889:Endometrial Neoplasms / Q000175:diagnosis / Q000191:economics / Q000401:mortality / Q000628:therapy*; D019317:Evidence-Based Medicine; D005260:Female; D019983:Guideline Adherence; D013509:Gynecologic Surgical Procedures / Q000191:economics; D017048:Health Care Costs; D006297:Health Services Accessibility; D054625:Healthcare Disparities; D020249:Hormone Replacement Therapy / Q000009:adverse effects / Q000191:economics; D006801:Humans; D008197:Lymph Node Excision; D008403:Mass Screening; D008495:Medical Oncology / Q000191:economics / Q000592:standards; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D018714:Radiotherapy, Adjuvant; D018570:Risk Assessment; D016896:Treatment Outcome